Trulieve Cannabis Corp. Elevates Profile with NYSE Listing on June 10, 2026

Trulieve's Historic Uplisting to the NYSE: What It Means for the Cannabis Industry

In a groundbreaking announcement, Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) has revealed that its subordinate voting shares will officially be listed on the New York Stock Exchange (NYSE) starting June 10, 2026, under the ticker symbol "TRLV." This moment marks a significant milestone for the medical cannabis sector, as Trulieve becomes the first U.S. cannabis company to achieve such a feat, opening the door for increased visibility and investment potential in the cannabis market.

Kim Rivers, the founder and CEO of Trulieve, expressed enthusiasm about this development. She highlighted that the reclassification of medical marijuana to Schedule III by President Trump was instrumental in facilitating this uplisting. Rivers stated, "As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity, and raise awareness for the benefits of medical marijuana."

The decision to uplist follows a series of regulatory changes that have gradually expanded the cannabis industry's landscape. In April 2026, acting Attorney General Todd Blanche officially reclassified medical marijuana products, setting a significant precedent for the industry. This decision, which followed an Executive Order by President Trump issued in December 2025, not only ups the ante for cannabis businesses but also provides a clear pathway for registration with the Drug Enforcement Administration (DEA).

Trulieve’s restructuring, adjusted in light of the recent legal developments, aims to focus strictly on state-licensed medical marijuana operations. The company now boasts 206 medical marijuana dispensaries and a significant production capacity of 3.5 million square feet, which are all registered with the DEA.

Rivers emphasized the company’s mission since its inception—serving medical patients with compassion and quality products. With robust cash generation and the promise of expansion into new states, including Georgia and Texas, Trulieve is poised for significant growth as it seeks to widen access to medical cannabis for U.S. patients.

From a trading perspective, Trulieve anticipates that its subordinate voting shares will also continue trading on the Canadian Securities Exchange under the symbol "TRUL" and on the OTCQX under "TCNNF" until the close of market on June 9, 2026. Current shareholders need not take any action for this transition, ensuring a smooth transition for existing investors.

The uplisting not only represents a strategic move for Trulieve but also a pivotal moment for the broader cannabis industry. It reflects ongoing shifts in regulations and societal attitudes towards cannabis and underscores the potential for growth and investment in this burgeoning market.

As Trulieve prepares for its NYSE debut, investors should keep an eye on its performance and the ensuing impact on the cannabis sector. The company’s commitment to quality and patient care may well set a new benchmark for the industry while opening the door to enhanced investment opportunities.

This pivotal development is a reminder of how rapidly the landscape can change in the cannabis sector, and Trulieve is leading the way in that transformation.